Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab Combined With GP ± Anlotinib in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05193617Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Aug 2022; status: active, not recruiting.
02
Drugs
anlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05193617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05193617.